SAGE Quote, Financials, Valuation and Earnings

Biogen has a net margin of -747.33% compared to Sage Therapeutics's net margin of 10.87%. Sage Therapeutics's return on equity of -63.59% beat Biogen's return on equity of 10.33%.

Sage Therapeutics has a consensus price target of $8.10, signalling upside risk potential of 13.15%. On the other hand Biogen has an analysts' consensus of $197.16 which suggests that it could grow by 71.19%. Given that Biogen has higher upside potential than Sage Therapeutics, analysts believe Biogen is more attractive than Sage Therapeutics.

Sage Therapeutics has a beta of 0.477, which suggesting that the stock is 52.304% less volatile than S&P 500. In comparison Biogen has a beta of 0.057, suggesting its less volatile than the S&P 500 by 94.303%.

Sage Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sage Therapeutics pays -- of its earnings as a dividend. Biogen pays out -- of its earnings as a dividend.

Sage Therapeutics quarterly revenues are $12.8M, which are smaller than Biogen quarterly revenues of $2.5B. Sage Therapeutics's net income of -$95.8M is lower than Biogen's net income of $266.7M. Notably, Sage Therapeutics's price-to-earnings ratio is -- while Biogen's PE ratio is 10.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sage Therapeutics is 10.55x versus 1.74x for Biogen. Usually stocks with elevated PS ratios are considered overvalued.

Cytokinetics has a net margin of -747.33% compared to Sage Therapeutics's net margin of -886.28%. Sage Therapeutics's return on equity of -63.59% beat Cytokinetics's return on equity of --.

Sage Therapeutics has a consensus price target of $8.10, signalling upside risk potential of 13.15%. On the other hand Cytokinetics has an analysts' consensus of $78.95 which suggests that it could grow by 104.27%. Given that Cytokinetics has higher upside potential than Sage Therapeutics, analysts believe Cytokinetics is more attractive than Sage Therapeutics.

Sage Therapeutics has a beta of 0.477, which suggesting that the stock is 52.304% less volatile than S&P 500. In comparison Cytokinetics has a beta of 0.938, suggesting its less volatile than the S&P 500 by 6.231%.

Sage Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cytokinetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sage Therapeutics pays -- of its earnings as a dividend. Cytokinetics pays out -- of its earnings as a dividend.

Sage Therapeutics quarterly revenues are $12.8M, which are smaller than Cytokinetics quarterly revenues of $16.9M. Sage Therapeutics's net income of -$95.8M is higher than Cytokinetics's net income of -$150M. Notably, Sage Therapeutics's price-to-earnings ratio is -- while Cytokinetics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sage Therapeutics is 10.55x versus 233.78x for Cytokinetics. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of -747.33% compared to Sage Therapeutics's net margin of 15.24%. Sage Therapeutics's return on equity of -63.59% beat Johnson & Johnson's return on equity of 19.98%.

Sage Therapeutics has a consensus price target of $8.10, signalling upside risk potential of 13.15%. On the other hand Johnson & Johnson has an analysts' consensus of $169.87 which suggests that it could grow by 11.96%. Given that Sage Therapeutics has higher upside potential than Johnson & Johnson, analysts believe Sage Therapeutics is more attractive than Johnson & Johnson.

Sage Therapeutics has a beta of 0.477, which suggesting that the stock is 52.304% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.490, suggesting its less volatile than the S&P 500 by 50.995%.

Sage Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.27% to investors and pays a quarterly dividend of $1.24 per share. Sage Therapeutics pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sage Therapeutics quarterly revenues are $12.8M, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. Sage Therapeutics's net income of -$95.8M is lower than Johnson & Johnson's net income of $3.4B. Notably, Sage Therapeutics's price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 26.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sage Therapeutics is 10.55x versus 4.15x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of -747.33% compared to Sage Therapeutics's net margin of -117.16%. Sage Therapeutics's return on equity of -63.59% beat Moderna's return on equity of -29.09%.

Sage Therapeutics has a consensus price target of $8.10, signalling upside risk potential of 13.15%. On the other hand Moderna has an analysts' consensus of $52.05 which suggests that it could grow by 98.66%. Given that Moderna has higher upside potential than Sage Therapeutics, analysts believe Moderna is more attractive than Sage Therapeutics.

Sage Therapeutics has a beta of 0.477, which suggesting that the stock is 52.304% less volatile than S&P 500. In comparison Moderna has a beta of 2.231, suggesting its more volatile than the S&P 500 by 123.128%.

Sage Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sage Therapeutics pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Sage Therapeutics quarterly revenues are $12.8M, which are smaller than Moderna quarterly revenues of $956M. Sage Therapeutics's net income of -$95.8M is higher than Moderna's net income of -$1.1B. Notably, Sage Therapeutics's price-to-earnings ratio is -- while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sage Therapeutics is 10.55x versus 3.18x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.